Ocuphire Pharma Results Presentation Deck

Percent of Subjects (%) Percent of Subjects With ≥ 2-Step Improvement in DRSS From Baseline ZETA-1 Did Not Meet the Week 24 Phase 2 Primary Endpoint (based on Anti-VEGF Precedence for DR) 35% 30% 25% 20% 15% 10% 5% 0% Percent of Subjects With ≥ 2-step Improvement in DRSS From Baseline by Visit (mITT) - Study Eye 0% n=47 p=0.27 4% n=46 Week 12 Visit Placebo (N=49) 8% n=40 p=0.93 8% n=39 Week 24 APX3330 (N=46) Percent of Subjects (%) 35% 30% 25% 20% 15% 10% 5% 0% Percent of Subjects With ≥ 2-step Improvement in DRSS From Baseline by Visit (mITT) - Qualified Fellow Eye 4% n=24 p=0.20 14% n=14 Week 12 Visit Placebo (N=49) 5% n=22 p=0.20 27% n=11 Week 24 ■APX3330 (N=46) Source: ZETA-1 Clinical Trial Note: Large "N" indicates total number of participants within each arm for the mITT population. Small "n" indicates total number of evaluable eyes for each respective endpoint and arm. Note: Images from Central Reading Center will be reviewed prior to EOP2 FDA meeting 15 Ocuphire

View entire presentation